Evidence map›Paper›PMID 28865435›Full record

ArticleBMC cancer2017

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.

Chang Gon Kim, Joong Bae Ahn, Sang Joon Shin, Seung Hoon Beom, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Eun Ah Choe, Woong Sub Koom, Hyuk Hur and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 5 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Changes in fatigue in rectal cancer patients before and after therapy: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Chang Gon KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Joong Bae AhnDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Sang Joon ShinDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Seung Hoon BeomDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Su Jin HeoDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Hyung Soon ParkDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Jee Hung KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Eun Ah ChoeDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Woong Sub KoomDepartment of Radiation Oncology, Yonsei Cancer Center, Seoul, South Korea.
Hyuk HurDepartment of Surgery, Yonsei Cancer Center, Seoul, South Korea.
Byung Soh MinDepartment of Surgery, Yonsei Cancer Center, Seoul, South Korea.
Nam Kyu KimDepartment of Surgery, Yonsei Cancer Center, Seoul, South Korea.
Hoguen KimDepartment of Pathology, Yonsei Cancer Center, Seoul, South Korea.
Chan KimDivision of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, South Korea.
Inkyung JungDepartment of Biostatistics and Medical Informatics, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. IJUNG@yuhs.ac.
Minkyu JungDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. MINKJUNG@yuhs.ac.
Yonsei University · KRCHA Bundang Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME).

methodsPatients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant and observation groups. To control for potential confounding factors, we also calculated propensity scores and performed propensity score-matched analysis for DFS and OS.

resultsOf the 339 evaluated patients, 87 patients (25.7%) did not receive AC. There were no differences in DFS (hazard ratio [HR], 0.921; 95% confidence interval [CI], 0.562-1.507; P = 0.742) and OS (HR, 0.835; 95% CI, 0.423-1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS (HR, 1.129; 95% CI, 0.626-2.035; P = 0.688) and OS (HR, 1.200; 95% CI, 0.539-2.669; P = 0.655) did not differ between the adjuvant and observation groups. Advanced T stage and positive resection margin were independently associated with inferior DFS and OS on multivariate analysis.

conclusionsAC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer should be evaluated in prospective randomized trials with a larger sample size.

Indexed as

AdultAgedAged, 80 and overChemoradiotherapyChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalFemaleFluorouracilHumansMaleMiddle AgedRectal NeoplasmsRectumFluorouracilAdjuvant chemotherapyDisease-free survivalOverall survivalRectal cancer

Identifiers

PMID28865435
PMCPMC5581409
OpenAlexW2750811186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.